Five pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Ocera Therapeutics, Inc. (OCRX) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. In Portfolio Grader’s specific subcategory of Earnings Revisions, OCRX also gets an A. For more information, get Portfolio Grader’s complete analysis of OCRX stock.
Johnson & Johnson (JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb Company (BMY) is seeing ratings go up from a C last week to a B this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals’ (WPI) ratings are looking better this week, moving up to an A from last week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Repros Therapeutics’ (RPRX) ratings are up from a B last week to an A. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.